

Available online at www.sciencedirect.com



Tetrahedron

Tetrahedron 64 (2008) 4590-4595

www.elsevier.com/locate/tet

Selective reduction and functionalization of diethyl 1-alkyl-1*H*-indole-2,3-dicarboxylates

Iliyas Ali Sayyed, Karolin Alex, Annegret Tillack, Nicolle Schwarz, Anke Spannenberg, Dirk Michalik, Matthias Beller*

Leibniz-Institut für Katalyse e.V. an der Universität Rostock, Albert-Einstein-Str. 29a, D-18059 Rostock, Germany

Received 25 January 2008; received in revised form 28 February 2008; accepted 3 March 2008 Available online 7 March 2008

Abstract

A convenient and highly selective reduction of easily accessible indole-2,3-dicarboxylates is described. Ten different 1-alkyl-2-formyl-1*H*-indole-3-carboxylates are obtained in high yield and represent interesting building blocks for novel indoles. © 2008 Elsevier Ltd. All rights reserved.

1. Introduction

Indole and its derivatives have been termed as 'privileged pharmacologic structures' since they bind to many biological receptors with high affinity.¹ In addition, the indole moiety is found in numerous natural products and is an important building block of several families of alkaloids.² Many of them have significant biological activity such as Indomethacin³ (anti-inflammatory), Vincristine⁴ (anti-cancer), Fluvastatin⁵ (cholesterol-lowering), Vinblastine⁶ (anti-cancer), and tryptophan, which is an essential amino acid⁷ (Scheme 1).



Scheme 1. Selected biologically active indoles.

Due to their importance as one of the most represented building blocks in natural products and known marketed drugs, there is a continuing interest in the development of

improved methods for the synthesis of indoles.^{8,9} In recent years especially domino sequences provided efficient complementary access to various indoles.¹⁰ Though, many catalytic methods exist for the preparation of indoles, still the most famous route for the construction of the indole ring constitutes the Fischer indole synthesis.⁹

For some time, we have been interested in the improvement and exploration of methodologies for the synthesis and functionalization of indoles. For example, we developed a titanium-catalyzed as well as zinc-mediated synthesis of functionalized tryptamines and tryptophol derivatives starting from commercially available arylhydrazines and alkynes.¹¹ More recently, we reported also a transition-metal-free one-pot synthesis of indole-2,3-dicarboxylates **1** from arylhydrazines and acetylene dicarboxylates.¹² Based on this work, we became interested in the selective reduction of indole-2,3-dicarboxylates (Scheme 2). Obviously, such a selective protocol would offer direct access to a variety of novel indole derivatives. Here, we report our results on this project.

Clearly, reduction of carboxylic acids, esters, and amides is an essential tool for the synthesis of aldehydes, alcohols, and amines.¹³ Especially, selective reduction to aldehydes is important, as the highly reactive formyl group can be easily employed in numerous C–C-, and C–N-coupling reactions as well as other transformations.

As shown in Scheme 2, chemoselective reduction of 1*H*-indole-2,3-dicarboxylates **1** could provide different functionalized

^{*} Corresponding author. Tel.: +49 (0)381 1281113; fax: +49 (0)381 12815000.

E-mail address: matthias.beller@catalysis.de (M. Beller).



Scheme 2. Potential reductions of the indole-2,3-dicarboxylates.

indoles such as 1-alkyl-1*H*-indole-2,3-dicarbaldehyde **2**, (1-al-kyl-1*H*-indole-2,3-diyl)-dimethanol **3**, 1-alkyl-2,3-dimethyl-1*H*-indole **4**, isomeric 2,3-formylindole-carboxylates **5** or **6**, and 2,3-hydroxymethylindole-carboxylates **7** or **8**.

2. Results and discussion

At the starting point of our investigations, we studied the reaction of indole 2,3-diester **1a** in the presence of standard metal hydrides at different temperatures. However, in the presence of NaBH₄ and NaCNBH₃ only the recovered starting material was obtained.

Unfortunately, under more drastic conditions treatment of 1a with LiAlH₄ (reflux temperature) afforded a complex mixture of several products.

As shown in Table 1 reduction using DIBAL-H at room temperature was more selective but also afforded a mixture of products. Here, aldehyde **5a** and alcohol **7a** along with the recovered starting material are observed. When the reduction was carried out in the presence of an excess (2.5 equiv) of DIBAL-H at -78 °C for 5 min, full conversion is seen and the alcohol **7a** is obtained as major product in 60% yield along with some aldehyde **5a**. Reducing the amount of DIBAL-H

 Table 1

 Reduction of 1a under different conditions

1a	CO ₂ Et	reduction DIBAL-H	5a	CO ₂ Et CHO +	Ta Me	P₂Et −CH₂OH
Entry	DIBAL-H (equiv)	Temp (°C)	Time (min)	Yield ^a (%) (5a)	Yield ^a (%) (7a)	Yield ^a (%) (1a)
1	1.5	0	5	23	24	50
2	2.0	0	5	9	40	49
3	2.5	-78	5	30	60	_
4	2.0	-78	5	60	30	_
5	2.0	-78	3	90	_	

^a Isolated yield.

(2.0 equiv) as well as the reaction time (3 min) afforded the aldehyde **5a** with an excellent yield of 90% as the only product of the reaction. To the best of our knowledge, there is no report on chemoselective reduction of one of the ester group of indole-2,3-dicarboxylates to give 2-formyl-1-alkyl-1*H*-indole-3-carboxylates.

Table 2
Chemoselective reduction of indole-2,3-dicarboxylates: substrate scope ^a



 $^{^{\}rm a}$ Reaction conditions: indole 2,3-dicarboxylates (1.0 equiv), DIBAL-H (2.0 equiv), CH_2Cl_2, -78 °C, 3 min. $^{\rm b}$ Isolated yield.



Figure 1. X-ray crystal structure of ethyl 2-formyl-1-methyl-1*H*-indole-3-carboxylate **5a**. The thermal ellipsoids correspond to 30% probability.

At this point, it should be noted that there are only few methods known in the literature for the preparation of 2-formyl-indole-3-carboxylates.¹⁴

The promising results obtained with the model compound encouraged us to study the general scope and limitations of this protocol for the reduction of different substituted indole-2,3-dicarboxylates (Table 2). Fluoro-, chloro-, and bromosubstituted diethyl indole-2,3-dicarboxylates 1g-1i readily underwent reduction with DIBAL-H to afford the corresponding aldehydes 5g-5i in good yield (67-90% yield) with no over-reduction of the halide substituents observed. Likewise, the nitro-substituted indole 1j gave the corresponding aldehyde 5j in 60% isolated yield. Previously, the product 1j has been obtained by nitration of 1a.¹⁵ Noteworthy, all isolated indole-2-aldehydes are stable solids, which did not oxidize easily in air. In all cases, spectroscopic characterization of the products by NMR revealed the presence of one aldehyde and one ester group. The position of the formyl group is established unambiguously by NOE measurements. For example, in the two-dimensional NOESY spectrum of 5d correlations are found for the proton H-4 with methyl substituent on the phenyl ring, the OCH₂, and the OCH₂CH₃ confirming the ester group being placed in C-3 position. In addition, we were able to confirm the regioselective reduction by X-ray crystallographic analysis of **5a** (Fig. 1).¹⁶ Suitable crystals were obtained by recrystallization from dichloromethane.

Obviously, 2-formyl indole-3-carboxylates are versatile building blocks for selective reactions either at the 2- or 3-position of the indole ring. Therefore, we turned our attention to further functionalization reactions of **5a**. In some preliminary studies, the reductive amination with benzylamine in the presence of NaCNBH₃ proceeded smoothly at the formyl group to give 10 in 80% yield (Scheme 3). Notably, there is no side reaction at the ester group observed.

Moreover, addition of organometallic reagents progressed highly selectively at the 2-position. Hence, the reaction of the vinyl magnesium bromide with **5a** yielded the corresponding allylic alcohol **9** in 82%. As expected in the NOESY spectrum of compound **9** correlations are found for the proton H-4 with OCH₂ and OCH₂CH₃ as well as NMe with the protons H-7, H-9, H-10, and H-11 confirming the proposed structure.

3. Conclusion

In conclusion, we have developed a convenient and fast reduction of 1H-indole-2,3-dicarboxylates. The resulting products **5a**-**j** are obtained with excellent selectivity in good yield. It is predicted that alkyl 2-formyl-1-alkyl-1*H*-indole-3carboxylates constitute useful building blocks, which will lead in three easy steps to a variety of novel 2,3-disubstituted indoles from commercially available arylhydrazines and acetylene dicarboxylates.

4. Experimental

4.1. General

All reactions were carried out under an argon atmosphere. Chemicals were purchased from Aldrich, Fluka, Acros, and Strem, and unless otherwise noted were used without further purification. All compounds were characterized by ¹H NMR, ¹³C NMR, MS, HRMS, and IR spectroscopy. ¹H and ¹³C NMR spectra were recorded on Bruker AV 300, AV 400, and AV 500 spectrometers. The ¹H and ¹³C NMR chemical shifts are reported relative to the center of solvent resonance (CDCl₃: 7.25 (¹H), 77.0 (¹³C)). For compounds 5d, 9, and **10**, a complete assignment of the ¹H- and ¹³C-signal is given based on two-dimensional NMR spectra (COSY, NOESY, and C,H-correlation). EI mass spectra were recorded on an AMD 402 spectrometer (70 eV, AMD Intectra GmbH). IR spectra were recorded on an FTIR Nicolet 6700 (Thermo ELECTRON CORPORATION). GC was performed on a Hewlett-Packard HP 6890 chromatograph with a 30 m HP5 column. All yields reported in Tables 1 and 2 refer to isolated yields.

4.2. General procedure for the preparation of aldehydes

A solution of diethyl 1-alkyl-1*H*-indole-2,3-dicarboxylate (0.25 mmol) in CH_2Cl_2 at -78 °C was treated with DIBAL-H (0.42 ml, 0.5 mmol, 1 M solution in toluene). The reaction



Scheme 3. Potential reduction examples of the indole-2,3-dicarboxylates.

4593

mixture was stirred at -78 °C for 3 min and then quenched with 1 M HCl and MeOH. After warming up to room temperature, H₂O was added and the aqueous layer was extracted three times with Et₂O. The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated in vacuo. Chromatography on silica gel with hexane–EtOAc (95:5) as the eluent afforded the aldehydes **5a**–**j**.

4.2.1. Ethyl 2-formyl-1-methyl-1H-indole-3-carboxylate (5a)

Isolated yield: 90% (mp: 76–77 °C). ¹H NMR (400 MHz, CDCl₃): δ (ppm)=1.47 (t, *J*=7.2 Hz, 3H), 4.05 (s, 3H), 4.45 (q, *J*=7.2 Hz, 2H), 7.26–7.45 (m, 3H), 8.23 (br d, *J*=8.0 Hz, 1H), 10.77 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ (ppm)=14.4 (CH₃), 32.5 (CH₃), 60.8 (CH₂), 110.5 (CH), 115.0, 123.2 (CH), 123.8 (CH), 125.5, 126.9 (CH), 136.3, 136.7, 164.3, 186.5 (CHO). MS (EI, 70 eV): *m/z* (relative intensity)=231 (M⁺, 76), 203 (21), 202 (42), 188 (21), 186 (32), 175 (26), 159 (16), 158 (100), 157 (26), 131 (16), 130 (17), 103 (12), 89 (12), 77 (12). HRMS (EI) calcd for C₁₃H₁₃NO₃: 231.0890; found: 231.0889. FTIR: (KBr, cm⁻¹)= 3077, 3025, 2987, 2906, 1699, 1662, 1612, 1516, 1447, 1396, 1383, 1338, 1267, 1218, 1175, 1160, 1106, 1036, 908, 890, 785, 752, 740, 726, 517.

4.2.2. Ethyl 1-benzyl-2-formyl-1H-indole-3-carboxylate (5b)

Isolated yield: 62% (mp: 112-113 °C). ¹H NMR (400 MHz, CDCl₃): δ (ppm)=1.48 (t, J=7.2 Hz, 3H), 4.48 (q, J=7.2 Hz, 2H), 5.87 (s, 2H), 7.04 (m, 2H), 7.17-7.42 (m, 6H), 8.31 (br d, J=8.0 Hz, 1H), 10.83 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ (ppm)=14.4 (CH₃), 48.4 (CH₂), 60.9 (CH₂), 111.2 (CH), 115.9, 123.3 (CH), 123.9 (CH), 125.7, 126.4 (2CH), 127.2 (CH), 127.5 (CH), 128.6 (2CH), 135.8, 136.8, 138.6, 164.2, 186.1 (CHO). MS (EI, 70 eV): m/z (relative intensity)=307 (M⁺, 16), 262 (12), 261 (42), 260 (37), 233 (14), 232 (36), 204 (17), 157 (11), 149 (37), 123 (48), 121 (18), 119 (21), 115 (14), 111 (15), 109 (15), 105 (22), 97 (23), 95 (29), 91 (100), 83 (29), 81 (24), 77 (27), 69 (71), 57 (50). HRMS (EI) calcd for C₁₉H₁₇NO₃: 307.1208; found: 307.1202. FTIR: (KBr, cm⁻¹)=3058, 3030, 2932, 1699, 1671, 1518, 1469, 1450, 1415, 1384, 1338, 1274, 1238, 1175, 1161, 1146, 1026, 913, 868, 785, 747, 730.

4.2.3. Ethyl 2-formyl-1-phenyl-1H-indole-3-carboxylate (5c)

Isolated yield: 75% (mp: 83–84 °C). ¹H NMR (300 MHz, CDCl₃): δ (ppm)=1.48 (t, *J*=7.2 Hz, 3H), 4.50 (q, *J*=7.2 Hz, 2H), 7.05 (m, 1H), 7.22–7.37 (m, 4H), 7.51 (m, 3H), 8.36 (m, 1H), 10.75 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm)=14.5 (CH₃), 61.0 (CH₂), 111.9 (CH), 115.9, 123.6 (CH), 123.6 (CH), 125.4, 127.2 (CH), 127.6 (2CH), 128.8 (CH), 129.3 (2CH), 136.7, 137.4, 139.8, 164.3, 184.3 (CHO). MS (EI, 70 eV): *m*/*z* (relative intensity)=293 (M⁺, 32), 264 (40), 248 (36), 247 (95), 237 (12), 221 (15), 220 (100), 219 (53), 218 (35), 193 (18), 191 (49), 190 (20), 165 (27), 158 (15), 77 (12), 57 (13), 55 (10). HRMS (EI) calcd for C₁₈H₁₅NO₃: 293.1046; found: 293.1044. FTIR: (KBr, cm⁻¹)=3054, 2980, 2952, 2899, 1700, 1679, 1597, 1516,

1502, 1482, 1454, 1395, 1381, 1343, 1263, 1241, 1183, 1123, 1065, 1020, 1065, 1020, 940, 773, 753, 698, 562.

4.2.4. Ethyl 1-benzyl-2-formyl-5-methyl-1H-indole-3-carboxylate (5d)

Isolated yield: 75% (mp: 97-98 °C). ¹H NMR (500 MHz, CDCl₃): δ (ppm)=1.48 (t, ³J=7.2 Hz, 3H, OCH₂CH₃), 2.48 (s, 3H, Me₍₈₎), 4.49 (q, ${}^{3}J=7.2$ Hz, 2H, OCH₂), 5.87 (s, 2H, H-8), 7.04 (m, 2H, o-Ph), 7.18-7.25 (m, 4H, H-6, m-, p-Ph), 7.30 (d, ${}^{3}J_{67}$ =8.5 Hz, 1H, H-7), 8.09 (br s, 1H, H-4), 10.79 (s, 1H, CHO). ¹³C NMR (125.8 MHz, CDCl₃): δ (ppm)=14.5 (OCH₂CH₃), 21.7 (Me₍₈₎), 48.5 (C-8), 60.8 (OCH₂), 110.9 (C-7), 115.3 (C-3), 123.1 (C-4), 126.0 (C-3), 126.4 (o-Ph), 127.5 (p-Ph), 128.7 (m-Ph), 129.3 (C-6), 133.1 (C-5), 135.7 (C-2), 137.0, 137.2 (C-7a, i-Ph), 164.4 (COO), 186.1 (CHO). MS (EI, 70 eV): *m/z* (relative intensity)=321 (M⁺, 28), 276 (18), 275 (71), 274 (62), 256 (57), 247 (20), 218 (15), 111 (14), 97 (20), 95 (16), 91 (100), 83 (20), 71 (20), 69 (22), 57 (31), 55 (28). HRMS (EI) calcd for C₂₀H₁₉NO₃: 321.1359; found: 321.1358. FTIR: (KBr, cm^{-1})=3066, 3033, 2985, 2922, 1693, 1669, 1515, 1482, 1452, 1413, 1384, 1351, 1304, 1270, 1234, 1164, 1133, 1030, 1011, 909, 871, 799, 772, 718, 694.

4.2.5. Ethyl 1-benzyl-2-formyl-5-isopropyl-1H-indole-3-carboxylate (5e)

Isolated yield: 86% (mp: 73-74 °C). ¹H NMR (400 MHz, CDCl₃): δ (ppm)=1.31 (d, J=7.0 Hz, 6H), 1.49 (t, J=7.2 Hz, 3H), 3.05 (sep, J=7.0 Hz, 1H), 4.49 (q, J=7.2 Hz, 2H), 5.85 (s, 2H), 7.05 (m, 2H), 7.19-7.35 (m, 5H), 8.15 (m, 1H), 10.80 (s, 1H). 13 C NMR (100 MHz, CDCl₃): δ (ppm)=14.4 (CH₃), 24.2 (2 CH₃), 34.2 (CH), 48.5 (CH₂), 60.8 (CH₂), 111.0 (CH), 115.5, 120.3 (CH), 125.9, 126.4 (2CH), 127.0 (CH), 127.4 (CH), 128.6 (2CH), 135.6, 136.9, 137.4, 144.2, 164.3, 186.0 (CHO). MS (EI, 70 eV): m/z (relative intensity)=349 (M⁺, 34), 304 (21), 303 (80), 302 (90), 276 (12), 275 (16), 274 (64), 260 (17), 232 (10), 91 (100), 65 (11). HRMS (EI) calcd for C₂₂H₂₃NO₃: 349.1672; found: 349.1669. FTIR: (KBr, cm⁻¹)=3064, 3033, 2959, 2929, 2870, 1701, 1671, 1621, 1606, 1516, 1482, 1454, 1411, 1383, 1353, 1282, 1235, 1187, 1163, 1130, 1030, 998, 906, 890, 806, 705.

4.2.6. Ethyl 1-benzyl-2-formyl-5-methoxy-1H-indole-3-carboxylate (**5f**)

Isolated yield: 60% (mp: $101-102 \circ C$). ¹H NMR (400 MHz, CDCl₃): δ (ppm)=1.48 (t, J=7.2 Hz, 3H), 3.89 (s, 3H), 4.48 (q, J=7.2 Hz, 2H), 5.86 (s, 2H), 7.02–7.09 (m, 3H), 7.22–7.33 (m, 4H), 7.73 (d, J=2.0 Hz, 1H), 10.78 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ (ppm)=14.4 (CH₃), 48.6 (CH₂), 55.6 (CH₃), 60.8 (CH₂), 103.2 (CH), 112.2 (CH), 114.9, 119.3 (CH), 126.4 (2CH), 126.7, 127.5 (CH), 128.7 (2CH), 134.1, 135.6, 136.9, 156.7, 164.4, 185.9 (CHO). MS (EI, 70 eV): *m/z* (relative intensity)=337 (M⁺, 35), 292 (14), 291 (51), 290 (53), 263 (17), 262 (47), 149 (11), 97 (14), 91 (100), 83 (18), 71 (16), 69 (22), 57 (28). HRMS (EI) calcd for C₂₀H₁₉NO₄: 337.1308; found: 337.1301. FTIR: (KBr, cm⁻¹)=3117, 3030, 3007, 2981, 2927, 2843, 1697, 1661, 1617, 1575, 1509, 1487, 1467, 1408, 1384, 1342, 1303, 1219, 1205, 1179, 1148, 1126, 1081, 1031, 988, 918, 867, 846, 816, 775, 742, 711.

4.2.7. Ethyl 1-benzyl-2-formyl-5-fluoro-1H-indole-3-carboxylate (**5g**)

Isolated yield: 90% (mp: 103-104 °C). ¹H NMR (400 MHz, CDCl₃): δ (ppm)=1.49 (t, J=7.2 Hz, 3H), 4.49 (q, J=7.2 Hz, 2H), 5.87 (s, 2H), 7.03 (m, 2H), 7.16 (dt, $J_{\rm H\,F}$ =9.0 Hz, J=9.0, 2.5 Hz, 1H), 7.22-7.28 (m, 3H), 7.35 (dd, J=9.0 Hz, $J_{H,F}=4.5$ Hz, 1H), 7.94 (dd, $J_{H,F}=9.5$ Hz, J=2.5 Hz, 1H), 10.84 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ (ppm)=14.4 (CH₃), 48.7 (CH₂), 61.0 (CH₂), 108.5 (d, J_{F,C}=25.2 Hz, CH), 112.5 (d, J_{F,C}=9.5 Hz, CH), 115.5 (d, $J_{\rm EC}$ =5.5 Hz), 116.5 (d, $J_{\rm EC}$ =27.4 Hz, CH), 126.2 (d, J_{F,C}=11.0 Hz), 126.4 (2CH), 127.7 (CH), 128.7 (2CH), 135.1, 136.5, 136.8, 159.6 (d, $J_{\rm FC}$ =241.0 Hz), 163.9, 186.1 (CHO). MS (EI, 70 eV): m/z (relative intensity)=325 (M⁺, 28), 280 (20), 279 (72), 278 (65), 251 (20), 250 (61), 222 (24), 92 (10), 91 (100), 65 (16). HRMS (EI) calcd for C₁₉H₁₆FNO₃: 325.1108; found: 325.1100. FTIR: (KBr, cm^{-1})=3105, 3043, 2982, 2926, 1705, 1657, 1513, 1493, 1461, 1413, 1390, 1260, 1237, 1214, 1176, 1160, 1144, 1126, 1028, 993, 939, 876, 857, 810, 786, 714.

4.2.8. Ethyl 1-benzyl-2-formyl-5-chloro-1H-indole-3-carboxylate (**5h**)

Isolated yield: 67% (mp: 88–89 °C). ¹H NMR (400 MHz, CDCl₃): δ (ppm)=1.47 (t, *J*=7.2 Hz, 3H), 4.47 (q, *J*=7.2 Hz, 2H), 5.84 (s, 2H), 7.00 (m, 2H), 7.14–7.33 (m, 5H), 8.27 (br s, 1H), 10.80 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ (ppm)=14.4 (CH₃), 48.7 (CH₂), 61.1 (CH₂), 112.4 (CH), 115.2, 123.2 (CH), 126.4 (2CH), 126.5, 127.7 (CH), 127.8 (CH), 128.8 (2CH), 129.4, 136.4, 136.5, 136.9, 163.8, 186.0 (CHO). MS (EI, 70 eV): *m/z* (relative intensity)=341 (M⁺, 20), 297 (16), 296 (28), 295 (46), 294 (48), 267 (20), 266 (37), 204 (10), 91 (100), 65 (13). HRMS (EI) calcd for C₁₉H₁₆ClNO₃: 341.0813; found: 341.0811. FTIR: (KBr, cm⁻¹)=3101, 3068, 3057, 2958, 2983, 2925, 2856, 1695, 1676, 1515, 1499, 1462, 1453, 1412, 1384, 1347, 1291, 1259, 1233, 1160, 1129, 1069, 1031, 996, 987, 923, 877, 866, 801, 781, 759, 738, 701.

4.2.9. Ethyl 1-benzyl-2-formyl-5-bromo-1H-indole-3-carboxylate (5i)

Isolated yield: 67% (mp: 109–110 °C). ¹H NMR (300 MHz, CDCl₃): δ (ppm)=1.48 (t, *J*=7.2 Hz, 3H), 4.49 (q, *J*=7.2 Hz, 2H), 5.85 (s, 2H), 7.01 (m, 2H), 7.20–7.30 (m, 4H), 7.47 (dd, *J*=9.0, 2.0 Hz, 1H), 8.45 (d, *J*=2.0 Hz, 1H), 10.82 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm)= 14.4 (CH₃), 48.6 (CH₂), 61.1 (CH₂), 112.8 (CH), 115.0, 117.1, 126.3 (2CH), 126.4 (CH), 127.0, 127.7, 128.8 (2CH), 130.3, 136.3, 136.4, 137.1, 163.8, 186.0 (CHO). MS (EI, 70 eV): *m/z* (relative intensity)=387 (M⁺², 15), 385 (M⁺, 15), 341 (39), 340 (39), 339 (39), 338 (28), 312 (28), 310 (22), 304 (12), 91 (100), 65 (10). HRMS (EI) calcd for

4.2.10. Ethyl 1-methyl-2-formyl-5-nitro-1H-indole-3-carboxylate (**5***j*)

Isolated yield: 60% (mp: 185–186 °C). ¹H NMR (400 MHz, CDCl₃): δ (ppm)=1.49 (t, *J*=7.2 Hz, 3H), 4.20 (s, 3H), 4.50 (q, *J*=7.2 Hz, 2H), 8.16 (dd, *J*=9.0, 2.0 Hz, 1H), 8.40 (d, *J*=9.0 Hz, 1H), 8.42 (d, *J*=2.0 Hz, 1H), 10.87 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ (ppm)=14.4 (CH₃), 33.0 (CH₃), 61.3 (CH₂), 107.6 (CH), 114.7, 117.7 (CH), 124.6 (CH), 129.5, 137.3, 139.7, 146.3, 163.4, 186.8 (CHO). MS (EI, 70 eV): *m/z* (relative intensity)=276 (M⁺, 56), 248 (23), 247 (23), 220 (30), 203 (100), 202 (28), 185 (20), 157 (25), 128 (18), 102 (12), 87 (11). FTIR: (KBr, cm⁻¹)=3121, 3091, 1703, 1672, 1515, 1471, 1406, 1397, 1340, 1260, 1218, 1162, 1123, 1070, 1027, 933, 887, 837, 736.

4.3. Ethyl 2-(1-hydroxyallyl)-1-methyl-1H-indole-3-carboxylate (9)

To a solution of ethyl 2-formyl-1-alkyl-1H-indole3-carboxylate (0.151 mmol) in 5 mL dry THF at -78 °C was treated with allyl-magnesium-bromide (0.166 mmol). The reaction mixture was stirred at -78 °C for 30 min. After removal of the solvent and purification by column chromatography (eluent: hexane-EtOAc=80:20) yielded 9 (82%) as colorless oil. ¹H NMR (500 MHz, CDCl₃): δ (ppm)=1.48 (t, ³*J*=7.2 Hz, 3H, Me), 3.78 (s, 3H, NMe), 4.38–4.48 (m, 2H, OCH₂), 5.15-5.21 (m, 2H, H-11), 5.70 (m, 1H, H-9), 6.17 $(ddd, {}^{3}J_{10,11(trans)} = 17.0 \text{ Hz}, {}^{3}J_{10,11(cis)} = 10.4 \text{ Hz}, {}^{3}J_{9,10} =$ 5.7 Hz, 1H, H-10), 6.35 (d, J=10.5 Hz, 1H, OH), 7.25-7.31 (m, 2H, H-5,6), 7.34 (m, 1H, H-7), 8.13 (m, 1H, H-4). ¹³C NMR (125.8 MHz, CDCl₃): δ (ppm)=14.4 (Me), 30.6 (NMe), 60.6 (OCH₂), 68.1 (C-9), 104.1 (C-3), 109.7 (C-7), 115.7 (C-11), 122.0 (C-4), 122.3 (C-5), 122.9 (C-6), 126.3 (C-3a), 136.6 (C-7a), 137.4 (C-10), 149.0 (C-2), 167.7 (CO). MS (EI, 70 eV): m/z (relative intensity)=259 (M⁺, 36), 214 (24), 213 (100), 186 (29), 185 (31), 184 (54), 170 (10), 169 (13), 168 (15), 158 (21), 157 (23), 130 (10). HRMS (EI) calcd for C₁₅H₁₇NO₃: 259.1202; found: 259.1200. FTIR: (neat, cm^{-1})=3409, 3054, 2980, 2936, 1689, 1661, 1523, 1472, 1404, 1376, 1351, 1330, 1287, 1219, 1163, 1104, 1032, 990, 928, 878, 790, 753, 741.

4.4. Ethyl 2-(benzylamino)methyl-1H-indole-3-carboxylate (10)

A solution of ethyl 2-formyl-1-alkyl-1*H*-indole-3-carboxylate (0.216 mmol), benzylamine (0.259 mmol), and NaCNBH₃ (0.216 mmol) in 6 mL methanol was stirred for 20 h at room temperature. After removal of the solvent and purification by column chromatography (eluent: EtOAc) yielded **10** (80%) as colorless oil. ¹H NMR (500 MHz, CDCl₃): δ (ppm)=1.43 (t, ³*J*=7.2 Hz, 3H), 2.24 (br, 1H, NH), 3.73 (s, 3H, Me₍₈₎), 3.89 (s, 2H, H-10), 4.27 (s, 2H, H-9), 4.42 (q, ${}^{3}J$ =7.2 Hz, 2H, OCH₂), 7.26–7.40 (m, 8H, H-5,6,7,Ph), 8.17 (m, 1H, H-4). 13 C NMR (125.8 MHz, CDCl₃): δ (ppm)=14.5 (Me), 29.8 (Me₍₈₎), 42.8 (C-9), 53.5 (C-10), 59.6 (OCH₂), 105.0 (C-3), 109.5 (C-7), 121.8 (2), 122.6 (C-4,5,6), 126.2 (C-3a), 127.0 (*p*-Ph), 128.2 (*o*-Ph), 128.3 (*m*-Ph), 136.7 (C-7a), 140.0 (*i*-Ph), 145.9 (C-2), 165.8 (CO). MS (EI, 70 eV): *m/z* (relative intensity)=325 (26), 280 (16), 279 (56), 278 (61), 252 (11), 251 (17), 250 (53), 222 (23), 91 (100), 65 (14). FTIR: (neat, cm⁻¹)=3300, 3105, 3042, 3031, 2925, 1704, 1657, 1513, 1492, 1461, 1452, 1412, 1389, 1372, 1351, 1260, 1236, 1214, 1176, 1160, 1143, 1126, 1027, 993, 939, 875, 856, 810, 784, 736, 713.

Acknowledgements

This work has been supported by the State of Mecklenburg-Western Pomerania, the BMBF (Bundesministerium für Bildung und Forschung), the Deutsche Forschungsgemeinschaft (Graduiertenkolleg and Leibniz-price), and the Fonds der Chemischen Industrie (FCI). We thank all the members of the analytical group for their support.

References and notes

- (a) Horton, D. A.; Bourne, G. T.; Smythe, M. L. *Chem. Rev.* 2003, *103*, 893–930; (b) Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Verber, D. F.; Abderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. H.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. J. Med. Chem. 1988, *31*, 2235–2246.
- (a) Gupta, R. R. *Heterocyclic Chemistry*; Springer: New York, NY, 1999; Vol. 2, p 193; (b) Rahman, A.; Basha, A. *Indole Alkaloids*; Harwood Academic: Amsterdam, The Netherlands, 1998; p 141.
- Physicians Desk Reference, 51st ed.; Medical Economics: Oradell, New Jersey, NJ, 1997; p 2395.
- Physicians Desk Reference, 51st ed.; Medical Economics: Oradell, New Jersey, NJ, 1997; p 1723.
- (a) Gupta, R. R. *Heterocyclic Chemistry*; Springer: New York, NY, 1999; Vol. 2, p 192; (b) *Physicians Desk Reference*, 51st ed.; Medical Economics: Oradell, New Jersey, NJ, 1997; p 1521.
- For a review on medicinal chemistry of Vinblastine, see: *The Alkaloids: Antitumor Bisindole Alkaloids from Catharanthus roseus (L.)*; Brossi, A., Suffness, M., Eds.; Academic: San Diego, CA, 1990; Vol. 37, pp 133–204.
- Meister, A. *The Biochemistry of the Amino Acids*, 2nd ed.; Academic: New York, NY, 1965; p 202.
- Selected recent examples: (a) Cariou, K.; Ronan, B.; Mignani, S.; Fensterbank, L.; Malacria, M. Angew. Chem. 2007, 119, 1913–1916; Angew. Chem., Int. Ed. 2007, 46, 1881–1884; (b) Yin, Y.; Ma, W.; Chai, Z.; Zhao, G. J. Org. Chem. 2007, 72, 5731–5736; (c) Liu, K. G.; Robicahud, A. J.; Lo, J. R.; Mattes, R. F.; Cai, Y. Org. Lett. 2006, 8, 5769–5771; (d) Kaspar, L. T.; Ackermann, L. Tetrahedron 2005, 61, 11311–11316; (e) Campos, K. R.; Woo, J. C. S.; Lee, S.; Tillyer, R. D. Org. Lett. 2004, 6, 79–82; (f) Hong, K. B.; Lee, C. W.; Yum, E. K. Tetrahedron Lett. 2004, 45, 693–697; (g) Cacchi, S.; Fabrizi, G.; Parisi, L. M. Org. Lett. 2003, 5, 3843–3846; (h) Siebeneicher, H.; Bytschkov, I.; Doye, S. Angew. Chem. 2003, 115, 3151–3153; Angew. Chem., Int. Ed. 2003,

42, 3042–3044; (i) Onitsuka, K.; Suzuki, S.; Takahashi, S. *Tetrahedron Lett.* 2002, 43, 6197–6199; (j) Rutherford, J. F.; Rainka, M. P.; Buchwald, S. L. J. Am. Chem. Soc. 2002, 124, 15168–15169; (k) Tokunaga, M.; Ota, M.; Haga, M.; Wakatsuki, Y. *Tetrahedron Lett.* 2001, 42, 3865–3868; (l) Verspui, G.; Elbertse, G.; Sheldon, F. A.; Hacking, M. A. P. J.; Sheldon, R. A. Chem. Commun. 2000, 1363–1364; (m) Beller, M.; Breindl, C.; Riermeier, T. H.; Eichberger, M.; Trauthwein, H. Angew. Chem. 1998, 110, 3571–3573; Angew. Chem., Int. Ed. 1998, 37, 3389–3391.

- For reviews, see: (a) Ackermann, L. Synlett 2007, 507-526; (b) Humphrey, G. R.; Kuethe, J. T. Chem. Rev. 2006, 106, 2875-2911; (c) Gribble, G. W. J. Chem. Soc., Perkin Trans. 1 2000, 1045-1075; (d) Gilchris, T. L. J. Chem. Soc., Perkin Trans. 1 1999, 2849-2866; (e) Sundberg, R. J. Indoles; Academic: San Diego, CA, 1996; (f) Moody, C. J. Synlett 1994, 681-688; (g) Gribble, G. W. Contemp. Org. Synth. 1994, 145-172; (h) Pindur, U.; Adam, R. J. Heterocycl. Chem. 1988, 25, 1-8.
- (a) Linnepe, P.; Schmidt, A. M.; Eilbracht, P. Org. Biomol. Chem. 2006, 4, 302-313; (b) Ahmed, M.; Jackstell, R.; Seayad, A. M.; Klein, H.; Beller, M. Tetrahedron Lett. 2004, 45, 869-873; (c) Ackermann, L.; Born, R. Tetrahedron Lett. 2004, 45, 9541-9544; (d) Köhling, P.; Schmidt, A. M.; Eilbracht, P. Org. Lett. 2003, 5, 3212-3216; (e) Cao, C.; Shi, Y.; Odom, A. L. Org. Lett. 2002, 4, 2853-2856.
- (a) Alex, K.; Tillack, A.; Schwarz, N.; Beller, M. Angew. Chem. 2008, 120, 2337–2340; Angew. Chem., Int. Ed. 2008, 47, 2304–2307; (b) Schwarz, N.; Alex, K.; Sayyed, I. A.; Khedkar, V.; Tillack, A.; Beller, M. Synlett 2007, 1091–1095; (c) Lo, W. F.; Kaiser, H. M.; Spannenberg, A.; Beller, M.; Tse, M. K. Tetrahedron Lett. 2007, 48, 371–375; (d) Schwarz, N.; Pews-Davtyan, A.; Alex, K.; Tillack, A.; Beller, M. Synthesis 2007, 3722–3730; (e) Kaiser, H. M.; Lo, W. F.; Riahi, M.; Spannenberg, A.; Beller, M.; Tse, M. K. Org. Lett. 2006, 8, 5761–5764; (f) Khedkar, V.; Tillack, A.; Michalik, M.; Beller, M. Tetrahedron 2005, 61, 7622–7631; (g) Khedkar, V.; Tillack, A.; Michalik, M.; Beller, M. Tetrahedron Lett. 2004, 45, 3123–3126; (h) Tillack, A.; Jiao, H.; Garcia Castro, I.; Hartung, C. G.; Beller, M. Chem.—Eur. J. 2004, 10, 2409– 2420; (i) Kumar, K.; Zapf, A.; Michalik, D.; Tillack, A.; Arlt, M.; Beller, M. Org. Lett. 2004, 6, 7–10.
- Sayyed, I. A.; Alex, K.; Tillack, A.; Schwarz, N.; Michalik, D.; Beller, M. Eur. J. Org. Chem. 2007, 4525–4528.
- (a) Hudlicky, M. Reductions in Organic Chemistry; Wiley: New York, NY, 1984; (b) Comprehensive Organic Synthesis: Selectivity Strategy and Efficiency in Modern Organic Chemistry; Trost, B. M., Fleming, I., Eds.; Reduction; Pergamon: Oxford, 1992; Vol. 8; (c) Seyden-Penne, J. Reductions by the Alumino- and Borohydrides in Organic Synthesis, 2nd ed.; Wiley: New York, NY, 1997.
- (a) Kinugawa, M.; Arai, H.; Nishikawa, H.; Sakaguchi, A.; Ogasa, T. J. Chem. Soc., Perkin Trans. 1 1995, 2677–2678; (b) Johnson, T. B.; Mikeska, L. A. J. Am. Chem. Soc. 1919, 41, 810–817.
- Organikum—Organisch-chemisches Grundpraktikum, 21st ed.; Wiley-VCH: Weinheim, 2001; pp 358–361.
- 16. X-ray crystallographic study of complex 5a. Data were collected with an STOE-IPDS diffractometer using graphite-monochromated Mo Kα radiation. The structures were solved by direct methods [Sheldrick, G. M. SHELXS-97; University of Göttingen: Germany, 1997;] and refined by full-matrix least-squares techniques against F²; [Sheldrick, G. M. SHELXL-97; University of Göttingen: Germany, 1997;]. XP (BRUKER AXS) was used for structural representations. Space group P21/c, monoclinic, a=14.294(3), b=9.846(2), c=7.841(2) Å, β=101.05(3)°, V=1130.8(4) Å³, Z=4, ρ_{calcd}=1.358 g cm⁻³, 3972 reflections measured, 2048 were independent of symmetry, of which 1291 were observed (I>2σ(I)), R1=0.056, wR2 (all data)=0.151, 154 parameters. The crystallographic data for the structures reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. CCDC (3). Copies of the data can be obtained free of charge on application to http://www.ccdc.cam.ac.uk/data_request/cif.